www.innocyto.com

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

APC Human CD200R1 Protein (C-Fc)

Catalog Number:	815503, 815504
Size:	25 ug, 100 ug
Target Name:	CD200R, CRTR2, MOX2R, OX2R
Regulatory Status:	RUO

PRODUCT DETAILS

Application:	Flow Cytometry
Format:	Liquid, APC
Expression Host:	CHO
Species:	Human
Sources:	Recombinant Human CD200R1 (Ala27-Leu266) with C-terminus Fc-tag is expressed in CHO cell and conjugated to APC.
Accession Number:	Q8TD46
Molecular Weight:	The protein has a predicted molecular weight of 53.1 kDa. Under DTT-reducing conditions, it migrates at approximately 80-110 kDa on SDS-PAGE prior to conjugation.
Affinity Tag:	C-Fc
Formulation:	1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
Endotoxin level:	Not tested
Protein Concentration:	25μg size is bottled at 0.1mg/mL concentration. 100 μg size is bottled at lot specific concentration.
Storage and Handling:	Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

BACKGROUND INFORMATION

CD200R (CD200 receptor) is an inhibitory immune receptor that plays a crucial role in regulating immune responses and maintaining immune homeostasis. CD200R is primarily expressed on myeloid cells, including macrophages, dendritic cells, neutrophils, and mast cells, as well as on some T cell and B cell subsets. The receptor functions as a negative regulator of immune activation, delivering inhibitory signals that suppress inflammatory responses, cytokine production, and cellular activation. Upon binding to its ligand CD200, CD200R helps maintain immune tolerance, prevent excessive inflammation, and protect tissues from immune-mediated damage. This regulatory pathway is particularly important in immune-privileged sites such as the brain, eye, and placenta, where it helps prevent destructive inflammatory responses.

Structurally, CD200R is a type I transmembrane glycoprotein of approximately 40-45 kDa belonging to the immunoglobulin superfamily. The extracellular region contains two immunoglobulin-like domains (one IgV-like and one IgC-like domain) that mediate ligand binding. The protein features a single transmembrane domain and a cytoplasmic tail containing immunoreceptor

tyrosine-based inhibitory motifs (ITIMs) and an immunoreceptor tyrosine-based switch motif (ITSM). Upon ligand engagement, these motifs become phosphorylated and recruit protein tyrosine phosphatases such as SHP-1 and SHP-2, as well as the lipid phosphatase SHIP. These phosphatases then suppress activating signaling pathways, including those downstream of Toll-like receptors and Fc receptors, thereby dampening immune cell activation and inflammatory responses.

The primary and well-characterized ligand for CD200R is CD200 (also known as OX-2), a widely expressed glycoprotein found on various cell types including neurons, endothelial cells, lymphocytes, and some tumor cells. CD200 is also a member of the immunoglobulin superfamily with structural similarity to CD200R. The CD200-CD200R interaction is highly specific and delivers potent inhibitory signals to myeloid cells. This interaction is critical for regulating microglial activation in the central nervous system, controlling macrophage responses in peripheral tissues, and maintaining immune privilege in specialized anatomical sites.

In disease contexts, dysregulation of the CD200-CD200R axis has been implicated in various pathological conditions. Reduced CD200 expression or impaired CD200R signaling contributes to excessive inflammation in autoimmune diseases, neurodegenerative disorders such as Alzheimer's disease and multiple sclerosis, and chronic inflammatory conditions. Conversely, many cancers exploit this pathway by overexpressing CD200 to suppress antitumor immunity and evade immune surveillance. CD200 overexpression has been observed in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), melanoma, and various solid tumors, where it correlates with immune suppression and poor prognosis. Therapeutically, the CD200-CD200R pathway represents a dual-edged target. For cancer treatment, blocking antibodies against CD200 or CD200R are being developed to disrupt tumor immune evasion and enhance antitumor immunity. Conversely, CD200 agonists or CD200-Fc fusion proteins are being explored as treatments for autoimmune and inflammatory diseases, aiming to enhance inhibitory signaling and reduce pathological inflammation. Additionally, modulating this pathway shows promise in transplantation medicine for promoting graft tolerance and in neurodegenerative diseases for controlling neuroinflammation.